IGF1R and non-small cell lung carcinoma: In addition we provide evidence that dual blockade of the IR and IGF-1R using an ATP-competitive small molecule IR/IGF-1R inhibitor has improved efficacy at inhibiting NSCLC cell proliferation over that obtained by simultaneous inhibition of the IR and IGF1-R using selective monoclonal antibodies.